Association of inhaled corticosteroid use with first Pseudomonas aeruginosa isolation in eosinophilic bronchiectasis: a multicenter retrospective study.

Authors

Yawen Wang, Runqing Liu, Xiujuan Bian, Guoqing Zhang, Lili Hou, Jie Ren, Suqin Ben, Jiayue Wu, Rong Tang, Xiaoyan Liu, Ying Ding, Wenjuan Ouyang, Meihua Zhao, Wenping Wang, Jianwei Gao, Ping Shao, Ruomin Liao, Min Zhang, Fengming Ding

Published in

Respiratory medicine. Pages 109221. Oct 16, 2026. Epub Oct 16, 2026.

Abstract

The use of inhaled corticosteroids (ICS) in bronchiectasis patients with eosinophilic inflammation is controversial due to the potential risk of bronchial or pulmonary infection. This study examined the association between ICS use and first Pseudomonas aeruginosa isolation across strata of blood eosinophil count (BEC).
A multicenter retrospective study was conducted in patients with bronchiectasis, who were classified according to baseline BEC at cohort entry: HighBEC (≥ 300 cells/μL), InterBEC (100-299 cells/μL), and LowBEC (< 100 cells/μL). ICS use was identified from prescription records, and first P. aeruginosa isolation was defined as the first positive culture for P. aeruginosa from a lower respiratory tract sample after cohort entry. Multivariate Cox proportional hazards regression was used to quantify the risk of first P. aeruginosa isolation associated with ICS use.
Of 1,900 bronchiectasis patients assessed, 719 were analyzed: 194 (27.0%) received ICS, 525 (73.0%) did not. During follow-up, P. aeruginosa was detected in 69 (9.6%) patients. After adjustment for potential confounders and disease severity indicators, ICS use was associated with a significantly higher risk of first P. aeruginosa isolation in patients with BEC ≥ 100 cells/μL, using no ICS as reference (HighBEC: adjusted HR 4.15, 95% CI 1.29-13.38, P = 0.0172; InterBEC: adjusted HR 3.13, 95% CI 1.56-6.27, P = 0.0013), but not in LowBEC patients (adjusted HR 0.48, 95% CI 0.08-2.79, P = 0.4160). Propensity-matched analyses supported these findings.
ICS use was associated with an increased risk of first P. aeruginosa isolation in eosinophilic bronchiectasis, suggesting caution when prescribing ICS to these patients.

PMID:
42887613
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.